The text starts here.

威尼斯手机娱乐官网

09/05/2018
EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. ANNOUNCE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) APPROVAL OF LENVIMA® (LENVATINIB) FOR TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARC
08/23/2018
EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR LENVIMA® (LENVATINIB) AS FIRST-LINE TREATMENT IN ADULTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA
08/17/2018
澳门威尼斯人4427com
07/31/2018
EISAI SIGNS COLLABORATION AGREEMENT FOR ANTI-OBESITY AGENT LORCASERIN IN CHINA TO CY BIOTECH
07/31/2018
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA® in Combination with KEYTRUDA®
07/26/2018
EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER’S DISEASE AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018
07/26/2018
EISAI AND BIOGEN PRESENT DETAILED RESULTS FROM PHASE II CLINICAL STUDY OF ELENBECESTAT IN MCI AND MILD TO MODERATE ALZHEIMER’S DISEASE AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018
07/19/2018
LATEST DATA ON EISAI’S ALZHEIMER’S DISEASE / DEMENTIA PIPELINE TO BE PRESENTED AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018
06/21/2018
AbbVie and Eisai Announce the Launch of HUMIRA® for Subcutaneous Injection 20 mg Syringe 0.2 mL, A New Pediatric Formulation of HUMIRA®
06/04/2018
EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. ANNOUNCE DATA AT 2018 ASCO ANNUAL MEETING FROM INVESTIGATIONAL STUDIES OF LENVIMA® AND KEYTRUDA® COMBINATION THERAPY IN FOUR DIFFERENT TUMOR TYPES

39497.com